Value of anti-infective chemoprophylaxis in primary systemic vasculitis: What is the evidence?

Arthritis Research and Therapy

Volumn 11, Issue 5, 2009, Pages

  Moosig, Frank ^a   Holle, Julia U ^a   Gross, Wolfgang L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ACICLOVIR; ALEMTUZUMAB; AMPHOTERICIN; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; FLUCONAZOLE; GANCICLOVIR; GLUCOCORTICOID; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; LEVOFLOXACIN; METHOTREXATE; METHYLPREDNISOLONE; NYSTATIN; PENTAMIDINE; PLACEBO; POSACONAZOLE; PREDNISOLONE; PSEUDOMONIC ACID; PYRIDOXINE; RIFAMPICIN; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VARICELLA ZOSTER VACCINE; ANTIINFECTIVE AGENT;

ASPERGILLOSIS; CANDIDIASIS; CHEMOPROPHYLAXIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HERPES ZOSTER; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; INFECTION SENSITIVITY; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; REMISSION; REVIEW; RISK FACTOR; STAPHYLOCOCCUS INFECTION; SYSTEMIC MYCOSIS; SYSTEMIC VASCULITIS; TREATMENT INDICATION; TUBERCULOSIS; VARICELLA ZOSTER VIRUS; BACTERIAL INFECTION; CLINICAL TRIAL; IMMUNOLOGY; VIRUS INFECTION;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; HUMANS; SYSTEMIC VASCULITIS; VIRUS DISEASES;

EID: 75649126939     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2826     Document Type: Review

References (78)

1. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, Woude FJ, de Lind van Wijngaarden RA, Pusey CD, . European Vasculitis Study Group Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18:2180-2188. 10.1681/ASN.2007010090, 17582159, European Vasculitis Study Group.
2. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Del Favero A, . Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005, 353:977-987. 10.1056/NEJMoa044097, 16148283, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program.
3. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A, . Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005, 353:988-998. 10.1056/NEJMoa050078, 16148284, Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group.
4. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996, 100:193-196. 10.1016/S0002-9343(97)89458-2, 8629654.
5. Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, Planchon B, El Kouri D, Connan L, Dupond JL, De Wazieres B, Dien G, Duhamel E, Grosbois B, Jego P, Le Strat A, Capdeville J, Letellier P, Agron L. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000, 27:1484-1491.
6. Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 134:106-114.
7. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, Cohen P, Calabrese LH, Dickler H, Merkel PA, Fortin P, Flynn JA, Locker GA, Easley KA, Schned E, Hunder GG, Sneller MC, Tuggle C, Swanson H, Hernández-Rodríguez J, Lopez-Soto A, Bork D, Hoffman DB, Kalunian K, Klashman D, Wilke WS, Scheetz RJ, Mandell BF, Fessler BJ, Kosmorsky G, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002, 46:1309-1318. 10.1002/art.10262, 12115238.
8. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, Younge BR, Weyand CM, Goronzy JJ. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006, 54:3310-3318. 10.1002/art.22163, 17009270.
9. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU, . Infliximab-GCA Study Group Infliximab for maintenance of gluco-corticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146:621-630. Infliximab-GCA Study Group.
10. Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, López-Longo J, Figueroa M, Belzunegui J, Mola EM, Bonilla G. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67:625-630. 10.1136/ard.2007.082115, 18086726.
11. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004, 50:2296-2304. 10.1002/art.20300, 15248230.
12. Cohen P, Pagnoux C, Mahr A, Arène JP, Mouthon L, Le Guern V, André MH, Gayraud M, Jayne D, Blöckmans D, Cordier JF, Guillevin L, . French Vasculitis Study Group Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007, 57:686-693. 10.1002/art.22679, 17471546, French Vasculitis Study Group.
13. Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P, Godeau B, Ruel M, Vidal E, Piontud M, Ducroix JP, Lassoued S, Christoforov B, Babinet P. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997, 36:1290-1297. 10.1093/rheumatology/36.12.1290, 9448590.
14. Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Généreau T, Léon A, Bussel A. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995, 38:1638-1645. 10.1002/art.1780381116, 7488285.
15. Guillevin L, Fain O, Lhote F, Jarrousse B, Le Thi Huong D, Bussel A, Leon A. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 1992, 35:208-215. 10.1002/art.1780350214, 1346499.
16. Guillevin L, Jarrousse B, Lok C, Lhote F, Jais JP, Le Thi Huong Du D, Bussel A. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991, 18:567-574.
17. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoanti-body-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996, 7:33-39.
18. Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, Gross WL, Reinhold-Keller E, . German Network of Rheumatic Diseases Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007, 46:1087-1091. 10.1093/rheumatology/kem029, 17519271, German Network of Rheumatic Diseases.
19. WGET Research Group Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352:351-361. 10.1056/NEJMoa041884, 15673801, WGET Research Group.
20. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suárez LF, Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004, 65:1440-1448. 10.1111/j.1523-1755.2004.00534.x, 15086487.
21. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004, 43:315-320. 10.1093/rheumatology/keh009, 14963200.
22. Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004, 51:83-91. 10.1002/art.20082, 14872460.
23. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002, 47:326-332. 10.1002/art.10459, 12115164.
24. Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rheumatology (Oxford) 2001, 40:492-498. 10.1093/rheumatology/40.5.492, 11371656.
25. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B, Heller M, Gross WL. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000, 43:1021-1032. 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J, 10817555.
26. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, Lesavre P, Jacquot C, Bindi P, Bielefeld P, Desson JF, Détrée F, Dubois A, Hachulla E, Hoen B, Jacomy D, Seigneuric C, Lauque D, Stern M, Longy-Boursier M. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997, 40:2187-2198. 10.1002/art.1780401213, 9416856.
27. de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nölle B, Gross WL. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996, 39:2052-2061. 10.1002/art.1780391215, 8961911.
28. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996, 335:16-20. 10.1056/NEJM199607043350103, 8637536.
29. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995, 38:608-613. 10.1002/art.1780380505, 7748215.
30. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puéchal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L, . French Vasculitis Study Group Azathioprine or methotrexate mainenance for ANCA-associated vasculitis. N Engl J Med 2008, 359:2790-2803. 10.1056/NEJMoa0802311, 19109574, French Vasculitis Study Group.
31. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008, 67:1322-1327. 10.1136/ard.2007.081661, 18055469.
32. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:2461-2469. 10.1002/art.21142, 16052573.
33. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, Savage C, Pusey C, Jayne D. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004, 15:717-721. 10.1097/01.ASN.0000114554.67106.28, 14978174.
34. Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grünke M, Peter HH, Kalden JR, Göbel U, Drexler JM, Hotta O, Nowack R, Woude FJ. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003, 14:440-447. 10.1097/01.ASN.0000048716.42876.14, 12538745.
35. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C, . European Vasculitis Study Group European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with anti-neutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36-44. 10.1056/NEJMoa020286, 12840090, European Vasculitis Study Group.
36. Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, Brunkhorst R. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998, 41:1835-18344. 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q, 9778225.
37. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, . EUVAS (European Vasculitis Study Group) Pulse versus daily oral cyclophosphamide for induction of remission in Antineutrophil cytoplasmic antibody-associated vasculitis. Ann Int Med 2009, 150:670-680. EUVAS (European Vasculitis Study Group).
38. Charlier C, Henegar C, Launay O, Pagnoux C, Berezné A, Bienvenu B, Cohen P, Mouthon L, Guillevin L. Risk factors for major infections in Wegener's granulomatosis: analysis of 113 patients. Ann Rheum Dis 2008, 68:658-663. 10.1136/ard.2008.088302, 18504289.
39. Takizawa Y, Inokuma S, Tanaka Y, Saito K, Atsumi T, Hirakata M, Kameda H, Hirohata S, Kondo H, Kumagai S, Tanaka Y. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population. Rheumatology (Oxford) 2008, 47:1373-1378. 10.1093/rheumatology/ken231, 18577548.
40. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003, 49:703-708. 14558057, 10.1002/art.11388.
41. Schmidt J, Duhaut P, Smail V, Chatelain D, Bosshard S, Pellet H, Piette J, Ducroix J. Severe infections during giant cell arteritis course: incidence and mortalitiy. The prospective, multicentre double cohort GRACG study [abstract]. Ann Rheum Dis 2009, 68s:80.
42. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007, 66:605-617. 10.1136/ard.2006.062711, 17170053.
43. Moosig F, Lamprecht P, Gross WL. Wegener's granulomatosis: the current view. Clin Rev Allergy Immunol 2008, 35:19-21. 10.1007/s12016-007-8067-5, 18172776.
44. Ullrich S, Gustke H, Lamprecht P, Gross WL, Schumacher U, Ambrosch P, Laudien M. Severely impaired respiratory ciliar function in Wegener's granulomatosis. Ann Rheum Dis 2008, 68:1067-1071. 10.1136/ard.2008.096974, 19028765.
45. Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis. JAMA 2007, 298:655-669. 10.1001/jama.298.6.655, 17684188.
46. Van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008, 4:CD006216.
47. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of S. aureus and higher relapse rates in Wegener's granulomatosis. Ann Intern Med 1994, 120:12-17.
48. Pinching AJ, Rees AJ, Pussell BA, Lockwood CM, Mitchison RS, Peters DK. Relapses in Wegener's granulomatosis: the role of infection. BMJ 1980, 281:836-838. 10.1136/bmj.281.6244.836, 1714254, 7427471.
49. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutical experience with 85 patients for 21 years. Ann Intern Med 1983, 98:76-85.
50. DeRemee RA, McDonald TJ, Weiland LH. Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985, 60:27-32.
51. Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, Leavitt RY. Penumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995, 151:795-799.
52. Godeau B, Mainardi JL, Roudot-Thoraval F, Hachulla E, Guillevin L, Huong Du LT, Jarrousse B, Remy P, Schaeffer A, Piette JC. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis 1995, 54:991-994. 10.1136/ard.54.12.991, 1010066, 8546533.
53. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996, 71:5-13. 10.4065/71.1.5, 8538233.
54. Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis 2004, 4:42-48. 10.1186/1471-2334-4-42, 526257, 15488151.
55. Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 2000, 43:1841-1848. 10.1002/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q, 10943875.
56. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, . European Vasculitis Study Group EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2008, 68:310-317. 10.1136/ard.2008.088096, 18413444, European Vasculitis Study Group.
57. Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D'Cruz D, Guillevin L, Harper L, Jayne D, Luqmani R, Mooney J, Scott D, . BSR and BHPR Standards, Guidelines and Audit Working Group BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007, 46:1615-1616. 10.1093/rheumatology/kem146a, 17804455, BSR and BHPR Standards, Guidelines and Audit Working Group.
58. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-hiv-infected patients: Systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007, 82:1052-1059. 10.4065/82.9.1052, 17803871.
59. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000, 118:704-711. 10.1378/chest.118.3.704, 10988192.
60. Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum 2008, 59:1034-1039. 10.1002/art.23822, 18576286.
61. Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ 1973, 49:103-106. 2481071, 4363395.
62. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001, 12:848-855.
63. Mori T, Kameda H, Ogawa H, Iizuka A, Sekiguchi N, Takei H, Nagasawa H, Tokuhira M, Tanaka T, Saito Y, Amano K, Abe T, Takeuchi T. Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy. J Rheumatol 2004, 31:1349-1351.
64. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD, . Valganciclovir Solid Organ Transplant Study Group Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004, 4:611-620. 10.1111/j.1600-6143.2004.00382.x, 15023154, Valganciclovir Solid Organ Transplant Study Group.
65. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005, 143:870-880.
66. Ragozzino MW, Melton LJ, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982, 61:310-316.
67. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007, 57:1431-1438. 10.1002/art.23112, 18050184.
68. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284. 10.1056/NEJMoa051016, 15930418.
69. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - a randomized double-blind placebo-controlled study. Blood 2006, 107:1800-1805. 10.1182/blood-2005-09-3624, 1895699, 16282339.
70. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57:1-30.
71. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007, 356:1338-1343. 10.1056/NEJMct066061, 17392303.
72. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006, 173:707-717. 10.1164/rccm.200505-727SO, 16387806.
73. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006, 57:628-638. 10.1093/jac/dki491, 16459344.
74. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 2006, CD004920.
75. Ho KM, Rochford SA, John G. The use of topical nonab-sorbable gastrointestinal antifungal prophylaxis to prevent fungal infections in critically ill immunocompetent patients: a meta-analysis. Crit Care Med 2005, 33:2383-2392. 10.1097/01.CCM.0000181726.32675.37, 16215396.
76. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev 2002, CD002033. 12519566.
77. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, Benedetti A, Schwartzman K. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008, 149:689-697.
78. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE, . American College of Rheumatology American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784. 10.1002/art.23721, 18512708, American College of Rheumatology.